Notably, although anti-IL-21 also attenuated disease in other lupus-prone mouse models, Act1 levels were not reduced in those lupus mice, indicating that IL-21 is probably modulated by multiple pathways. This evidence concerns the gene TRAF3IP2 and systemic lupus erythematosus.